Review of ind application for ihl-42x by us fda has been completed; clinical trial for patients with obstructive sleep apnoea may proceed

Melbourne, australia, aug. 22, 2023 (globe newswire) -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), (‘incannex' or the ‘company') a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs, is pleased to announce that it has received approval from the us food and drug administration (‘fda') to conduct the company's investigational new drug (‘ind') opening pivotal ihl-42x phase 2/3 clinical trial in the united states as planned.
IXHL Ratings Summary
IXHL Quant Ranking